Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis

Lancet

Volumn 347, Issue 8998, 1996, Pages 347-352

  Ten Wolde, Saskia ^a   Breedveld, Ferdinand C ^a   Hermans, Jo ^a   Vandenbroucke, Jan P ^a   Van De Laar, Mart A F J ^b   Markusse, Harry M ^c   Janssen, Matthijs ^d   Van Den Brink, Hans R ^e   Dijkmans, Ben A C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d RIJNSTATE HOSPITAL   (Netherlands)

^e Northwest Clinics   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; AUROTHIOGLUCOSE; AZATHIOPRINE; CHLOROQUINE; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SYNOVITIS; TIME; TREATMENT OUTCOME; TREATMENT PLANNING; URTICARIA;

EID: 0030066368     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)90535-8     Document Type: Article

References (36)

1. Scull E. Chloroquine and hydroxychloroquine therapy in rheumatoid arthritis. Arthritis Rheum 1962; 5: 30-36.
2. Cooperating Clinics Committee of the ARA. A controlled trial of gold salt therapy in rheumatoid arthritis. Arthritis Rheum 1973; 16: 353-58.
3. Clark P, Casas E, Tugwell P, et al. Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med 1993; 119: 1067-71.
4. Hannonen P, Mottonen T, Hakola M, Oka M. Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 1993; 36: 1501-09.
5. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 818-22.
6. Urowitz MD, Gordon DA, Smythe HA, Pruzanski W, Ogryzio MA. Azathioprine in rheumatoid arthritis: a double-blind, cross over study. Arthritis Rheum 1973; 16: 411-18.
7. Rothermich NO, Thomas MH, Phillips VK, Bergen W. Clinical trial of penicillamine in rheumatoid arthritis. Arthritis Rheum 1981; 24: 1473-78.
8. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992; 19: 1885-94.
9. Gabriel SE, Luthra HS. Rheumatoid arthritis: can the long-term outcome be altered? Mayo Clin Proc 1988; 63: 58-68.
10. Hawley DJ, Wolfe F. Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome: analysis of 122 studies. J Rheumatol 1991; 18: 1008-14.
11. Pincus T. Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol 1988; 41: 1037-41.
12. Wijnands MJ, van 't Hof MA, van Leeuwen MA, van Rijswijk MH, van de Putte LB, van Riel PL. Long-term second-line treatment: a prospective drug survival study. Br J Rheumatol 1992; 31: 253-58.
13. Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 1991; 18: 188-94.
14. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1917 consecutive starts. J Rheumatol 1990; 17: 994-1002.
15. Porter DR, McInnes I, Hunter J, Capell HA. Outcome of second line therapy in rheumatoid arthritis. Ann Rheum Dis 1994; 53: 812-15.
16. De Silva M, Hazleman BL. Long-term azathioprine in rheumatoid arthritis: a double-blind study. Ann Rheum Dis 1981; 40: 560-63.
17. Cade R, Stein G, Pickering M, Schlein E, Spooner G. Low dose, long-term treatment of rheumatoid arthritis with azathioprine. South Med J 1976; 69: 388-92.
18. Ahern MJ, Hall ND, Case K, Maddison PJ. D-penicillamine withdrawal in rheumatoid arthritis. Anm Rheum Dis 1984; 43: 213-17.
19. Kremer JM, Rynes RI, Bartholomew LE. Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy. Am J Med 1987; 82: 781-86.
20. Szanto E. Low-dose methotrexate in rheumatoid arthritis: effect and tolerance. Scand J Rheumatol 1986; 15: 97-102.
21. Cats A. A multicenter controlled trial of the effects of different dosage of gold therapy, followed by a maintenance dosage. Agents Actions 1976; 6: 355-63.
22. Arnett FC, Edworthy SM, Block DA. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
23. Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 1308-15.
24. van der Leeden H, Dijkmans BAC, Hermans J, Cats A. A double-blind study on the effect of discontinuation of gold therapy in patients with rheumtoid arthritis. Clin Rheumatol 1986; 5: 56-61.
25. van de Stadt RJ, Abbo-Tilstra B. Gold binding to blood cells and serum proteins during chrysotherapy. Ann Rheum Dis 1980; 39: 31-36.
26. Ritchie DM, Boyule JA, McInnes JM, et al. Clinical studies with an articular index for the assessment of joint tenderness in patinets with rheumatoid arthritis. Q J Med 1968; 37: 393-406.
27. Siegert CEH, Vleming LJ, Vandenbroucke JP, Cats A. Measurement of disability in Dutch rheumatoid arthritis patients. Clin Rheumatol 1984; 3: 305-09.
28. Grindulis KA, McConkey B. Outcome of attempts to treat rheumatoid arthritis with gold, penicillamine, sulphasalazine, or dapsone. Ann Rheum Dis 1984; 43: 398-401.
29. Bax DE, Amos RS. Sulphasalazine in the long term management of rheumatoid arthritis. Drugs 1986; 32 (suppl 1): 73-76.
30. Cash JM, Klippel JH. Second-line therapy for rheumatoid arthritis. N Engl J Med 1994; 330: 1368-75.
31. Wolfe F, Hawley DJ. Remission in rheumatoid arthritis. J Rheumatol 1985; 12: 245-52.
32. Williams HJ, Ward JR, Reading JC, et al. Low-dose d-penicillamine therapy in rheumatoid arthritis: a controlled, double-blind clinical trial. Arthritis Rheum 1983; 26: 581-92.
33. Cats A, Hazevoet HM. Significance of positive tests for rheumatoid factor in the prognosis of rheumatoid arthritis. A follow-up study. Ann Rheum Dis 1970; 29: 254-60.
34. van Zeben D, Hazes JM, Zwinderman AH, Cats A, van der Voort EA, Breedveld FC. Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum Dis 1992; 51: 1029-35.
35. van Zeben D, Hazes JM, Zwinderman AH, Vandenbroucke JP, Breedveld FC. Factors predicting outcome of rheumatoid arthritis: results of a follow up study. J Rheumatol 1993; 20: 1288-96.
36. Paulus HE. An overview of benefit/risk of disease modifying treatment of rheumatoid arthritis as of today. Ann Rheum Dis 1982; 41 (suppl): 26-29.